Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Site Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4 in Healthy Adults At-Risk for Exposure to Francisella Tularensis.

Next Previous
Trial Profile

A Multi-Site Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4 in Healthy Adults At-Risk for Exposure to Francisella Tularensis.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tularaemia vaccine (Primary)
  • Indications Tularaemia
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 28 Apr 2021 Planned End Date changed from 1 Apr 2021 to 1 Dec 2021.
  • 02 Nov 2020 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
  • 13 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Apr 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top